Get the Stockscreener App
5.58
1.64%
-0.093
After Hours:
5.58
Eupraxia Pharmaceuticals Inc stock is traded at $5.58, with a volume of 5,589.
It is down -1.64% in the last 24 hours and up +5.28% over the past month.
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
See More
Previous Close:
$5.673
Open:
$5.56
24h Volume:
5,589
Relative Volume:
0.40
Market Cap:
$200.64M
Revenue:
-
Net Income/Loss:
$-25.50M
P/E Ratio:
-7.2468
EPS:
-0.77
Net Cash Flow:
$-30.10M
1W Performance:
+8.77%
1M Performance:
+5.28%
6M Performance:
+95.10%
1Y Performance:
+97.87%
1-Day Range:
$5.55
$5.58
1-Week Range:
$5.06
$5.69
52-Week Range:
$2.20
$6.1999
Eupraxia Pharmaceuticals Inc Stock (EPRX) Company Profile
Name
Eupraxia Pharmaceuticals Inc
Sector
Industry
Phone
-
Address
-
Compare EPRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EPRX
Eupraxia Pharmaceuticals Inc
|
5.58 | 203.37M | 0 | -25.50M | -30.10M | -0.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.34B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.14 | 60.31B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.55 | 42.35B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.79 | 36.43B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
305.74 | 31.87B | 3.81B | -644.79M | -669.77M | -6.24 |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-24-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-25 | Initiated | H.C. Wainwright | Buy |
| Jun-16-25 | Initiated | Canaccord Genuity | Speculative Buy |
| Feb-21-25 | Initiated | Craig Hallum | Buy |
| Nov-14-24 | Initiated | Rodman & Renshaw | Buy |
Eupraxia Pharmaceuticals Inc Stock (EPRX) Latest News
Eupraxia Pharmaceuticals Inc. stock daily chart insightsFree Profit Target Stock Opportunity Monitor - Newser
Signal strength of Eupraxia Pharmaceuticals Inc. stock in tech scannersFree Price Action Based Buy Opportunity List - Newser
Why Eupraxia Pharmaceuticals Inc. stock attracts strong analyst attentionPrice Forecast Based on AI Analysis - Newser
How Interest Rate Changes Impact Eupraxia Pharmaceuticals Inc. Stock PerformanceGrowth Watchlist for Long Term Positioning - Newser
What high frequency data says about Eupraxia Pharmaceuticals Inc.Yearly Trend Summary and Opportunity Breakdown - Newser
Is Eupraxia Pharmaceuticals Inc. stock a growth or value playBuy and Exit Strategy Based on Momentum - Newser
Why did EPRX's Q4 2024 earnings report show no surprise? - AInvest
Published on: 2025-07-29 10:20:51 - metal.it
Using Bollinger Bands to evaluate Eupraxia Pharmaceuticals Inc.Free Step-by-Step Stock Investment Guide - Newser
Is Eupraxia Pharmaceuticals Inc. forming a bottoming baseWeekly Price Target Forecast and Alerts - Newser
How volatile is Eupraxia Pharmaceuticals Inc. stock compared to the marketAchieve consistent double-digit returns - jammulinksnews.com
Cantor Fitzgerald Forecasts EPRX FY2025 Earnings - Defense World
Why is Eupraxia Pharmaceuticals Inc. stock attracting strong analyst attentionConsistent double returns - jammulinksnews.com
What institutional investors are buying Eupraxia Pharmaceuticals Inc. stockFree Investment Risk Control - jammulinksnews.com
How does Eupraxia Pharmaceuticals Inc. generate profit in a changing economyGet professional guidance for market timing - jammulinksnews.com
Is Eupraxia Pharmaceuticals Inc. Stock a Good Fit for Conservative InvestorsLow Risk High Reward Picks - Newser
Eupraxia Pharmaceuticals Inc. Earnings Report Breakdown: What Investors Should KnowHigh Return Setup Scanner - Newser
What makes Eupraxia Pharmaceuticals Inc. stock price move sharplyGrowth Optimized Stock Radar - Newser
Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives $11.00 Average Target Price from Analysts - Defense World
Eupraxia Pharmaceuticals (NASDAQ:EPRX) Coverage Initiated at Cantor Fitzgerald - Defense World
Is Eupraxia Pharmaceuticals Inc. a good long term investmentFree Trend-Following Techniques - PrintWeekIndia
Eupraxia Pharmaceuticals Inc. Stock Analysis and ForecastFree Stock Chart Pattern Guide - Autocar Professional
This Sarepta Therapeutics Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Thursday - Benzinga
What drives Eupraxia Pharmaceuticals Inc. stock priceExplosive earning power - jammulinksnews.com
(EPRX.WT.A) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
What analysts say about Eupraxia Pharmaceuticals Inc. stockHigh-yield capital appreciation - jammulinksnews.com
(EPRX) Market Dynamics and Trading Signals (EPRX:CA) - news.stocktradersdaily.com
Eupraxia Pharmaceuticals to Present at Key Investor Conferences - TipRanks
Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences - GlobeNewswire
Eupraxia Pharmaceuticals Secures Speaking Slots at Canaccord, Citi, Cantor, and H.C. Wainwright Conferences - Stock Titan
(EPRX.WT.A) Market Dynamics and Trading Signals - news.stocktradersdaily.com
Eupraxia Pharmaceuticals Inc Stock (EPRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
10.28%
2.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):